Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Zealand Pharma Halts Development of Dual GLP-1/GLP-2 Agonist Amid Competitive Obesity Treatment Landscape

Zealand Pharma has announced the suspension of development for its dual GLP-1/GLP-2 agonist, dapiglutide, citing an increasingly crowded metabolic development scene. The decision comes as part of a strategic move to focus resources on programs with greater potential for clinical differentiation and long-term value creation.

NoahAI News11/13/2025

Gilead's Single-Tablet HIV Regimen Shows Promise in Phase 3 Trial

Gilead Sciences has announced positive results from a phase 3 trial of its investigational single-tablet HIV regimen, combining bictegravir and lenacapavir (BIC/LEN). The study, known as Artistry-1, demonstrated that the once-daily tablet was non-inferior to complex multi-tablet regimens in maintaining viral suppression in adults with HIV.

NoahAI News11/13/2025

Sanara MedTech Restructures, Discontinues Tissue Health Platform

Sanara MedTech, a prominent player in the surgical products market, has announced a significant corporate restructuring, including the discontinuation of its Tissue Health Plus (THP) platform. This strategic move comes as part of the company's efforts to refocus on its core surgical business, which has demonstrated consistent growth over recent years.

NoahAI News11/13/2025

Biotech Funding Shifts Reshape Executive Search and Hiring Practices

In the ever-evolving landscape of the biotechnology industry, recent changes in funding dynamics are having a profound impact on executive search and hiring processes. As companies navigate a leaner financial environment, they are adopting more targeted and intentional approaches to building their leadership teams.

NoahAI News11/13/2025

Korro Bio Faces Setbacks: Lead Drug Disappoints, Novo Nordisk Partnership Paused

Korro Bio, a Massachusetts-based biotechnology company, has announced a series of significant setbacks, including disappointing results for its lead drug candidate and a pause in its partnership with Novo Nordisk. These developments have led to a substantial workforce reduction and a strategic pivot in the company's research focus.

NoahAI News11/13/2025

FDA Decisions Loom for Innovative Therapies in Rare Diseases and Cancer

The pharmaceutical industry is poised for a series of significant regulatory decisions this month, with the U.S. Food and Drug Administration (FDA) set to rule on several groundbreaking therapies. These potential approvals span rare genetic disorders, various cancers, and could reshape treatment landscapes in their respective fields.

NoahAI News11/13/2025

Massachusetts Life Sciences Companies Fall Short on Job Creation Targets, Facing Layoffs and Award Terminations

In a significant setback for the Massachusetts life sciences sector, nearly two dozen companies have failed to meet their hiring commitments tied to state tax incentives. This development comes amid a wave of layoffs affecting hundreds of jobs across the industry, signaling potential headwinds for the biotech hub.

NoahAI News11/13/2025

Biopharma Job Market Recovery Expected Sooner Amid M&A, IPOs, and FDA Approvals

Pharmaceutical Industry Sees Signs of Recovery Amid Ongoing ChallengesThe pharmaceutical industry is showing early signs of recovery, with experts predicting a potential turnaround in the job market by late 2026. However, significant challenges remain, and many industry professionals remain skeptical about the timeline for improvement.

NoahAI News11/13/2025

Novartis' GanLum: A Breakthrough in Malaria Treatment

Novartis has announced promising results from a phase 3 trial of its next-generation malaria treatment, GanLum, positioning the company to seek regulatory approval for what could be the first major innovation in malaria treatment in over two decades.

NoahAI News11/13/2025

Grail's Q3 Sales Surge as FDA Submission for Galleri Cancer Test Approaches

Grail, a California-based biotech company, has reported a significant increase in third-quarter sales, driven primarily by the growing adoption of its Galleri multicancer early detection blood test. The company also announced a more definitive timeline for its FDA submission, signaling potential advancements in cancer diagnostics and market expansion.

NoahAI News11/13/2025

Promega's MSI Diagnostic Wins FDA Approval as Companion Test for Keytruda-Lenvima Combo in Uterine Cancer

Promega Corporation has secured a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) approving its OncoMate MSI Dx Analysis system as a companion diagnostic for the combination therapy of Merck's Keytruda (pembrolizumab) and Eisai's Lenvima (lenvatinib) in advanced endometrial carcinoma. This approval marks a crucial step forward in precision medicine for uterine cancer patients and underscores the growing importance of biomarker-driven treatment strategies in oncology.

NoahAI News11/13/2025

Novartis Poised to Revolutionize Malaria Treatment with Novel Drug

Novartis, the Swiss pharmaceutical giant, is on the cusp of introducing the first new antimalarial drug in over two decades, following successful Phase 3 trial results. The company's innovative therapy, known as GanLum, has demonstrated high efficacy against drug-resistant parasites and the ability to impede disease transmission, potentially marking a significant breakthrough in the fight against malaria.

NoahAI News11/13/2025

«1...37 38 39...67 »